StockNews.AI

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

StockNews.AI • 2 days

SKYEJNJLLY
High Materiality8/10

Information

Agreement supports development and commercialization of higher-dose, subcutaneous administration str...

Original source

AI Summary

Halozyme Therapeutics and Skye Bioscience have announced a collaboration focusing on nimacimab's subcutaneous delivery for obesity treatment. Utilizing Halozyme's ENHANZE technology, the agreement involves milestone payments and ongoing royalties, highlighting the potential for expansion in the obesity market and reinforcing Halozyme's capabilities in drug delivery innovation.

Trading Thesis

The collaboration may enhance HALO's revenue potential from royalties and partnerships.

Market-Moving

  • Halocube's expansion into obesity market could drive stock price up.
  • Potential milestone payments from Skye could positively impact HALO's cash flow.
  • Increasing clinical focus on obesity treatments enhances growth narrative for HALO.
  • Successful Phase 2b trial results may boost investor confidence in HALO.
  • Partnership validates Halozyme's ENHANZE technology, raising its market appeal.

Key Facts

  • Collaboration announced for nimacimab's commercialization using ENHANZE technology.
  • HALO will receive mid-single digit royalties on nimacimab sales.
  • Skye plans Phase 2b clinical trial mid-2026 for nimacimab.
  • ENHANZE technology reduces injection volume for improved patient experience.
  • Halozyme has numerous strategic partnerships, enhancing its market presence.

Companies Mentioned

  • Halozyme Therapeutics (HALO): Involved in collaboration with Skye for nimacimab.
  • Skye Bioscience (SKYE): Licensing ENHANZE technology for higher-dose obesity treatment.
  • Johnson & Johnson (JNJ): Partnered for drug delivery innovations enhancing HALO's portfolio.
  • Eli Lilly (LLY): Engaged in developing advanced drug delivery technologies.

Corporate Developments

The collaboration falls under 'Corporate Developments' as it outlines a new strategic partnership that has important implications for HALO's market reach and potential revenue streams.

FAQ

Why Bullish?

The collaboration enhances HALO's product offerings and potential revenue through royalties. Historical partnerships in the biotech sector often lead to stock price appreciation following successful collaboration announcements.

How important is it?

This collaboration significantly strengthens HALO's position in the obesity market, indicating future revenue potential and innovation capacity. The strategic direction aligns with investor interests in growth sectors.

Why Long Term?

While immediate gains may be limited, the long-term potential for revenue growth through royalties and technology validation positions HALO for sustained success in new markets.

Related Companies

SKYEJNJLLY

Halozyme and Skye Bioscience Collaborate on Nimacimab for Obesity Treatment

Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) have announced a significant global collaboration and license agreement aimed at enhancing nimacimab's development for obesity treatment. This agreement, which was finalized in December 2025, involves the licensing of Halozyme's ENHANZE® drug delivery technology, facilitating a subcutaneous formulation of nimacimab.

Strategic Collaboration Focused on Higher-Dose Administration

The collaboration is primarily focused on the evaluation of higher subcutaneous doses of nimacimab, utilizing ENHANZE® technology to enable larger injection volumes. According to Dr. Helen Torley, President and CEO of Halozyme, this partnership significantly extends the reach of ENHANZE® into the rapidly expanding obesity market, which shows promising long-term growth potential.

"Our collaboration with Skye Bioscience expands the reach of our ENHANZE technology into the growing obesity market, a therapeutic area with significant long-term potential," stated Dr. Torley.

Goals and Financial Terms of the Agreement

As part of the agreement, Skye will make milestone payments contingent upon the successful completion of development and commercialization objectives. Additionally, Halozyme will receive mid-single digit royalties on net sales of nimacimab developed in conjunction with ENHANZE® for a minimum period of ten years. This partnership aligns with Halozyme's strategic aim to foster sustainable royalty growth through innovative collaborations.

Looking Ahead: Clinical Trials and Development Plans

Skye has announced plans to initiate a Phase 2b clinical trial in the middle of 2026 to evaluate nimacimab's efficacy in obesity treatment, including its combination with a GLP-1 receptor agonist. Punit Dhillon, President and CEO of Skye, emphasized the necessity of testing higher doses in a practical manner to fully assess nimacimab's potential.

"To fully evaluate nimacimab's potential, we need to test higher doses and we need a practical way to deliver them subcutaneously," noted Dhillon.

About Halozyme and Its Innovative Drug Delivery Technology

Halozyme is a biopharmaceutical firm dedicated to developing innovative solutions that improve patient experiences and therapeutic outcomes. The ENHANZE® technology, featuring the proprietary enzyme rHuPH20, enhances the subcutaneous delivery of drugs, consequently minimizing treatment burdens for patients. ENHANZE® has positively impacted over one million patients globally through ten commercialized products in over 100 markets.

  • Halozyme partners with major pharmaceutical and biotechnology firms including Roche and Pfizer.
  • The company is also advancing its Hypercon™ technology to further optimize drug delivery systems.
  • Halozyme's headquarters is located in San Diego, CA, with additional offices across the United States.

About Skye Bioscience

Skye Bioscience focuses on creating innovative therapies for metabolic health, developing next-generation molecules aimed at modulating G-protein coupled receptors. The company is currently conducting a Phase 2a clinical trial to explore nimacimab's effectiveness in obesity treatment.

Forward-Looking Statements

This announcement contains forward-looking statements regarding both companies' development goals and financial expectations. Factors influencing actual results include regulatory approvals, milestone achievements, and market competitiveness. Investors are advised to consult Halozyme and Skye's latest reports submitted to the Securities and Exchange Commission for further insights.

Contact Information

For more information, please reach out to:

  • Halozyme: Tram Bui, VP of Investor Relations — 609-359-3016
  • Skye Bioscience: Investor & Media Relations — (858) 410-0266

Related News